China-related policy and national security developments are creating new challenges for life sciences companies, with potential implications for clinical trials, regulatory approvals, research collaborations, and investment activity. In this episode of Choate’s Intellectual Property Insights podcast series, Christine Savage and Sara Frank discuss the latest U.S. government actions affecting China-linked activities, including congressional investigations into clinical trials conducted in China, proposed limits on FDA consideration of China-generated data, and increased scrutiny of biotech partnerships and research collaborations. They also examine the impact of the Biosecure Act, the Department of Defense’s 1260H list, and emerging outbound investment restrictions that could affect pharmaceutical companies, biotech investors, universities, and research institutions. For organizations operating in the life sciences sector, this conversation provides practical insights into a rapidly evolving regulatory and policy landscape. To download this podcast, click the three vertical dots to the right of the player above and select “Download.” For a transcript of this episode, please email your request to podcasts@choate.com.